Doxazosin Mesylate is an α-blocker drug related to prazosin, specifically acting as an AR (α-1-adrenoceptor) antagonist. Doxazosin Mesylate inhibits the binding of norepinephrine to the α-1 receptors on the membrane of vascular smooth muscle cells. The primary effect of this inhibition is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.
Doxazosin Mesylate
| Description | |
|---|---|
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-2-yl)methanone; methanesulfonic acid | |
| 77883-43-3 | |
| C24H29N5O8S | |
| 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate | |
| Doxazosin ER is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia | |
Copyright © 2014. All Rights Reserved at Jai Radhe Sales.
Powered by: Adit Microsys
